News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Multiple Myeloma

Latest News

Video Series

Ajay K. Nooka, MD, MPH, FACP

Dr Nooka on Integrating Bispecific Antibodies Into the Community Treatment Paradigm for Multiple Myeloma

Ajai Chari, MD

Dr Chari on the Risks and Benefits Associated With Earlier CAR T Use in R/R Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, FASCO

Dr Usmani on Challenges With Bispecifics and CAR T-Cell Therapies in Multiple Myeloma

Amrita Krishnan, MD

Dr Krishnan on Maintenance Approaches in Transplant-Ineligible Multiple Myeloma

A panel of 5 experts on multiple myeloma

Treatment Considerations and Sequencing in Multiple Myeloma

A panel of 5 experts on multiple myeloma

CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

A panel of 5 experts on multiple myeloma

GPRC5D-Targeting Bispecifics in Multiple Myeloma

A panel of 5 experts on multiple myeloma

Adverse Effects Related to Bispecifics in Multiple Myeloma

A panel of 5 experts on multiple myeloma

Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

A panel of 5 experts on multiple myeloma

Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

Latest Videos

Claudio Cerchione, MD, PhD, discusses the significance of the FDA approval of subcutaneous isatuximab in multiple myeloma.

Dr Cerchione on the FDA Approval of Subcutaneous Isatuximab in Myeloma

$Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses the potential role for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.$

Dr Spencer on the Potential Role for In Vivo CAR T-Cell Therapy in Myeloma

Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses efficacy data for the in vivo CAR T-cell therapy KLN-1010 in multiple myeloma.

Dr Spencer on Early Efficacy Data for In Vivo CAR T-Cell Therapy in R/R Myeloma

Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses key features of in vivo CAR T-cell therapy in multiple myeloma.

Dr Spencer on Differentiating Factors for In Vivo CAR T-Cell Therapy in Myeloma

Joshua Richter, MD, joins The Moonlight Shift to discuss the remarkable evolution of multiple myeloma treatment.

From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma

Talquetamab-Based Combos in R/R Myeloma | Image Credit: © LASZLO - stock.adobe.com

Dr Voorhees on Efficacy Data for Talquetamab-Based Combos in R/R Myeloma From MonumenTAL-3

Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.

Dr Chari on Navigating CAR T, Bispecifics, and Other Treatment Approaches in R/R Myeloma

$Diana Cirstea, MD, discusses sequencing considerations in relapsed/refractory multiple myeloma in the era of T-cell–redirecting therapies.$

Dr Cirstea on Sequencing Considerations in R/R Multiple Myeloma

Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.

Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma

Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.

Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma

Shorts

Peter Voorhees, MD

The Significance of the MajesTEC-9 Trial in R/R Myeloma

13 days ago

by

Peter Voorhees, MD

Assessing Data for In Vivo CAR T-Cell Therapy in Myeloma

Assessing Data for In Vivo CAR T-Cell Therapy in Myeloma

16 days ago

by

Andrew Spencer, MBBS, FRACP, FRCPA, DM

Noa Biran, MD

Diving into Key Multiple Myeloma Data From ASCO 2026

a month ago

by

Noa Biran, MD

Andrew Spencer, MBBS, FRACP, FRCPA, DM

The Potential of In Vivo CAR T-Cell Therapy in Multiple Myeloma

a month ago

by

Andrew Spencer, MBBS, FRACP, FRCPA, DM

Rahul Banerjee, MD, spotlights the phase 3 MonumenTAL-3 trial (NCT05455320) among the key multiple myeloma presentations to watch at the 2026 EHA Congress.

MonumenTAL-3 Leads Key Myeloma Data Set To Emerge at EHA 2026

a month ago

by

Rahul Banerjee, MD

Previewing ASCO 2026: SUCCESSOR-2 Trial in R/R Multiple Myeloma

Previewing ASCO 2026: SUCCESSOR-2 Trial in R/R Multiple Myeloma

2 months ago

by

Rahul Banerjee, MD

Previewing ASCO 2026: Myeloma Abstracts to Watch

Previewing ASCO 2026: Myeloma Abstracts to Watch

2 months ago

by

Diana Cirstea, MD

Sequencing T-Cell–Redirecting Therapies in Multiple Myeloma

Sequencing T-Cell–Redirecting Therapies in Multiple Myeloma

2 months ago

by

Diana Cirstea, MD

Treatment and Clinical Trial Considerations in Myeloma Subgroups

Treatment and Clinical Trial Considerations in Myeloma Subgroups

2 months ago

by

Rebecca Silbermann, MD, MMS

Frontline Treatment and Transplant Considerations in Multiple Myeloma

Frontline Treatment and Transplant Considerations in Multiple Myeloma

3 months ago

by

Ajai Chari, MD

Podcasts

Oncology Unplugged

Quadruplet Regimens and T-Cell Redirection Are on the Map of Myeloma Management Strategies: With Chandler Park, MD; Muhamed Baljevic, MD, FACP

Noa Biran, MD, breaks down key multiple myeloma data shared at the 2026 ASCO Annual Meeting.

Unpacking Key Multiple Myeloma Data From ASCO 2026: With Noa Biran, MD (VIDEO)

Joshua Richter, MD, previews some of the most anticipated multiple myeloma presentations ahead of the 2026 EHA Congress.

Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of daratumumab plus VRd for the treatment of newly diagnosed, transplant-ineligible multiple myeloma.

FDA Approval Insights: SC Daratumumab Plus VRd Provides Additional Treatment Avenue in Transplant-Ineligible, Newly Diagnosed Myeloma: With Saad Z. Usmani, MD, MBA, FACP, FASCO

Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Aila

January 30, 2026

Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD

Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington

January 16, 2026

Emerging CELMoDs Set New Standards for Efficacy and Tolerability in Myeloma: With Rahul Banerjee, MD, FACP

Pooja M. Phull, MD, hematologist/oncologist, John Theurer Cancer Center, Hackensack University Medical Center

December 18, 2025

Microbiome Profiling Highlights Impact of Butyrate Loss on Post-Transplant Outcomes in Multiple Myeloma: With Pooja M. Phull, MD

Joshua Richter, MD, associate professor, medicine, The Tisch Cancer Institute; director, Multiple Myeloma, Blavatnik Family Chelsea Medical Center, Mount Sinai

November 28, 2025

Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

November 24, 2025

Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

Mian

November 6, 2025

Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC

CME Content

Indiana Oncology Society

Indiana Oncology Society

2 Sessions are Available!

Minnesota Society of Clinical Oncology

Minnesota Society of Clinical Oncology

2 Sessions are Available!

South Carolina Oncology Society

South Carolina Oncology Society

2 Sessions are Available!

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Aditya Bardia, MD, MPH, FASCO; Bachar Samra, MD

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Sara A. Hurvitz, MD, FACP; Shaina Rozell, MD, MPH

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Kamel Abou Hussein, MD

Washington State Medical Oncology Society

Washington State Medical Oncology Society

1 Session is Available!

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Optimizing Treatment for Biliary Tract Cancers

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Cross-Disease Integration of Immunotherapy Innovations

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Arkansas Association of Cancer Professionals

Arkansas Association of Cancer Professionals

2 Sessions are Available!

North Carolina Oncology Association

North Carolina Oncology Association

2 Sessions are Available!

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Jacob Sands, MD; Anne Chiang, MD, PhD

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rutika Mehta, MD, MPH

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Geoffery Ku, MD; Shruti Patel, MD

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Rahul Gosain, MD, MBA; Rohit Gosain, MD

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Mark Agulnik, MD; Mrinal M. Gounder, MD; Sandra D’Angelo, MD; Sujana Movva, MD

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Mark Agulnik, MD; Lee M. Zuckerman, MD

Diagnosis and Management of TGCT

Diagnosis and Management of TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

Optimizing Multidisciplinary Care in TGCT

Optimizing Multidisciplinary Care in TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Naveen Pemmaraju, MD; Shannon Elf, PhD; Angela Fleischman, MD, PhD; Bethan Psaila, MD

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Case-based Simulation

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

More News

EHA 2026 | Image Credit: © Tongpoon - stock.adobe.com

Dive Into Key Data and Presentations From EHA 2026

ByOncLive Staff

July 13th 2026

Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.

FDA

FDA Accepts NDA for Mezigdomide Plus Kd in R/R Myeloma

ByOncLive Staff

July 13th 2026

The FDA accepted a new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.

Cancer | Image Credit: © catalin - stock.adobe.com

Revisit Every OncLive On Air Episode From June 2026

ByAshling Wahner

July 11th 2026

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

OncLive Weekly News Quiz (7/10/2026): Test Your Knowledge on Key Updates in Myeloma, MIBC, and More

ByOncLive Staff

July 10th 2026

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

FDA

FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma

July 10th 2026

The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.

EHA 2026 | Image Credit: © Curie - stock.adobe.com

Hematologists Detail Practice-Shaping Data That Emerged at EHA 2026 (VIDEO)

July 9th 2026

Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress

Andrew Spencer, MBBS, FRACP, FRCPA, DM

Phase 1 Data Highlight Potential Utility for In Vivo CAR T-Cell Therapy in R/R Myeloma

July 7th 2026

Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.

Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com

Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma

ByOncLive Staff

July 3rd 2026

Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.

Teclistimab Plus Daratumumab in Multiple Myeloma | Image Credit: © LELISAT - stock.adobe.com

Extended Teclistamab/Daratumumab Indication Approaches EU Approval in R/R Multiple Myeloma

June 26th 2026

CHMP backs teclistamab plus daratumumab for earlier use in relapsed/refractory multiple myeloma following strong MajesTEC-3 results.

Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com

Daratumumab Retreatment Displays Activity in Relapsed Myeloma Following Continuous Frontline Therapy

ByOncLive Staff

June 25th 2026

Daratumumab-based retreatment remained active in a broadly inclusive, transplant-ineligible newly diagnosed multiple myeloma population.

Multiple Myeloma | Image Credit: © Tongpoon - stock.adobe.com

Allogeneic BCMA CAR T-Cell Therapy CT0596 Elicits 100% ORR in R/R Myeloma and Plasma Cell Leukemia

ByOncLive Staff

June 23rd 2026

An off-the-shelf BCMA-directed CAR T-cell therapy generated a 100% overall response rate and universal MRD negativity in heavily pretreated myeloma.

The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.

Five Under 5: Top Oncology Videos for the Week of 6/14

ByOncLive Staff

June 21st 2026

The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.

Multiple Myeloma | Image Credit: © Tongpoon - stock.adobe.com

MonumenTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma

June 13th 2026

Talquetamab plus daratumumab, with or without pomalidomide, significantly improved PFS and deepened responses in relapsed/refractory myeloma.

Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com

CARTITUDE-4 Analysis Shows Bridging Therapy Response Predicts Cilta-Cel Benefit in Lenalidomide-Refractory Myeloma

ByOncLive Staff

June 12th 2026

Partial response to bridging therapy before cilta-cel was associated with improved PFS and OS outcomes in relapsed/refractory multiple myeloma.

KLN-1010 in R/R Myeloma: ©LASZLO - stock.adobe.com

In Vivo CAR T-Cell Therapy Drives Responses and MRD Negativity in R/R Myeloma

June 11th 2026

The in vivo CAR T-cell therapy KLN-1010 produced deep MRD-negative responses in relapsed/refractory multiple myeloma.

Subcutaneous Isatuximab Administered in Multiple Myeloma: ©LASZLO - stock.adobe.com

Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma

ByAshling Wahner

June 8th 2026

The EU has approved the use of subcutaneous isatuximab delivered via OBI across all existing indications for IV isatuximab for multiple myeloma.

Bipul Kumar - stock.adobe.com

Hematologists Highlight Top Data From ASCO 2026

June 8th 2026

Experts highlight some top hematologic oncology data presented at ASCO 2026, including from key studies in multiple myeloma and diffuse large B-cell lymphoma.

Multiple Myeloma | Image Credit: LASZLO - stock.adobe.com

Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026

June 4th 2026

Experts outline the key multiple myeloma presentations they are anticipating at the 2026 EHA Congress.

Myeloma | Image Credit: © LASZLO - stock.adobe.com

CEPHEUS Final Analysis: DVRd Sustains Efficacy Benefits in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

ByOncLive Staff

May 31st 2026

DVRd maintained efficacy benefits over VRd in transplant-ineligible, newly diagnosed multiple myeloma.

Myeloma | Image Credit: © Curie - stock.adobe.com

Mezigodomide-Based Regimen Delivers Significant Survival Benefits in R/R Multiple Myeloma

May 30th 2026

Mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed or refractory multiple myeloma.

Multiple myeloma | Image Credit: © LASZLO - stock.adobe.com

Teclistamab Monotherapy Tops SOC PVd/Kd in Myeloma, With Phase 3 Data Presented at ASCO 2026

Published: May 29th 2026 | Updated: May 29th 2026

Results from the phase 3 MajesTEC-9 trial show superior PFS, OS, and ORR outcomes with teclistamab monotherapy in pretreated relapsed/refractory myeloma.

Myeloma | Image Credit: © LASZLO - stock.adobe.com

BVRd Yields Strong Efficacy in Newly Diagnosed, Transplant-Ineligible Myeloma

ByOncLive Staff

May 29th 2026

Final analysis of DREAMM-9 shows promising efficacy data and an optimal dosing schedule for BVRd in transplant-ineligible newly diagnosed multiple myeloma.

Multiple Myeloma | Image Credit: LASZLO - stock.adobe.com

Novel GPRC5D-Directed CAR T-Cell Therapy Produces Durable Remissions in R/R Myeloma

ByOncLive Staff

May 27th 2026

RD118 produced an ORR of 94.4% and a median PFS of 18.2 months in heavily pretreated patients with relapsed/refractory multiple myeloma.

ASCO 2026 | Image Credit: © Brighting Collection - stock.adobe.com

Polls Reveal Picks for Top Hematologic Oncology Abstracts at ASCO 2026

ByOncLive Staff

May 22nd 2026

Poll results reflected some of the most anticipated presentations and fields of interest in hematologic oncology at the 2026 ASCO Annual Meeting.

Image credit: Om.Nom.Nom - stock.adobe.com

Frontline Combos Take the Spotlight: Previewing the Top Hematologic Oncology Presentations at ASCO 2026

ByChris Ryan,Riley Kandel

May 21st 2026

Hematologic oncology experts preview the top ASCO 2026 abstracts to watch in myeloma, MPNs, large B-cell lymphoma, and more.

Trending on OncLive

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer

Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC

How Are Treatment Intensification and Sequencing Reshaping Care in Prostate Cancer and RCC

NMPA Accepts Toripalimab Plus Chemotherapy Application for Expanded Stage II-III NSCLC Use